Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Recent News

Dec 05, 2016
- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – - NDA submission and launch preparation on track – -Conference call today at 8:00 a.m. EST-
Dec 05, 2016
- Posters Presented at American Epilepsy Society Annual Meeting - - New data includes key secondary efficacy endpoints -
Dec 01, 2016
- Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites - - GW will also unveil its new U.S. operating name, Greenwich Biosciences, Inc.  -

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Completed Phase 3
Epidiolex
Lennox-Gastaut Syndrome
Completed Phase 3
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioma
Phase 2
GWP42003
Schizophrenia
Completed Phase 2

Sativex (Partnered)

Sativex
Ms Spasticity
Approved